Slingshot members are tracking this event:
Merck's (MRK) Keytruda Approved By FDA for New Indication in Metastatic Non-Small Cell Lung Cancer (NSCLC) With High PD-L1 Expression and No EGFR or ALK Mutations
Slingshot Insights Explained
Oct 24, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Keytruda, Fda, Metastatic Non-small Cell Lung Cancer, Nsclc, High Pd-l1 Expression, No Egfr, Alk, Mutations